英国国民卫生服务体系药品准入后再评估制度研究与启示

张弛; 翁俊岭; 项予良; 杨毅; 陈英耀

doi:10.19546/j.issn.1674-3830.2026.3.014

中国医疗保险 ›› 2026, Vol. 0 ›› Issue (3) : 118-126. DOI: 10.19546/j.issn.1674-3830.2026.3.014

国际（地区）比较

英国国民卫生服务体系药品准入后再评估制度研究与启示

张弛^1,2, 翁俊岭^1,2, 项予良^1,2, 杨毅^1,2, 陈英耀^1,2

作者信息 +

Research and Enlightenment on the United Kingdom's National Health Service Post-Listing Reassessment System for Reimbursed Medicines

Author information +

文章历史 +

摘要

目的:梳理英国国民卫生服务体系中的药品准入后再评估制度路径，为我国构建相关机制提供经验借鉴。方法:查阅相关学术文献与官方资料，分析英国国民卫生服务体系药品准入后再评估的制度框架与实施路径。结果:英国一方面通过NICE指南常规监测识别证据变化，适时启动常规支付药品的再评估，并根据评估结果更新NICE指南;另一方面，对于签订管理准入协议的药品，依据协议设定的时限和要求开展再评估，综合临床试验与真实世界数据判断其临床与经济价值，决定是否纳入常规使用。结论及建议：我国应加快建立制度化的医保药品准入后再评估体系，明确其触发条件、组织架构、评估流程及评价结果的决策转化路径;健全医保目录药品再评估分类管理路径，推动附条件上市药品医保准入与再评估机制协同;强化真实世界数据赋能医保药品再评估的应用支持体系，助力医保治理体系的现代化与高质量发展。

Abstract

Objectives: The paper summarizes the post-listing reassessment framework for medicines under the United Kingdom’s National Health Service (NHS), with the aim of providing insights for establishing corresponding mechanisms in China. Methods:A review of relevant academic literature and official documents was conducted to analyze the policy framework and implementation pathways of post-listing reassessment of medicines in the NHS. Results:On the one hand, changes in the evidence base are identified through routine surveillance of NICE guidelines, which may trigger reassessment of routinely commissioned medicines and subsequent NICE guideline updates. On the other hand, for medicines covered by managed access agreements, reassessments are conducted according to predefined timelines and requirements specified in the agreements, integrating evidence from clinical trials and real-world data to assess clinical and economic value, and to inform decisions on transition to routine commissioning. Conclusionsand suggestions: China should accelerate the establishment of an institutionalized post-listing reassessment framework, clarifying its triggering conditions, organizational structure, evaluation processes, and pathways for translating reassessment results into decisions. It is also essential to improve classified management mechanisms for the reassessment of medicines on the reimbursement list, strengthen the synergy between conditional access and post-listing reassessment, and enhance the application support system for empowering reassessment with real-world data, thereby advancing the modernization and high-quality development of the healthcare security governance system.

导出引用

张弛, 翁俊岭, 项予良, 杨毅, 陈英耀. 英国国民卫生服务体系药品准入后再评估制度研究与启示[J]. 中国医疗保险. 2026, 0(3): 118-126 https://doi.org/10.19546/j.issn.1674-3830.2026.3.014

Research and Enlightenment on the United Kingdom's National Health Service Post-Listing Reassessment System for Reimbursed Medicines[J]. China Health Insurance. 2026, 0(3): 118-126 https://doi.org/10.19546/j.issn.1674-3830.2026.3.014

中图分类号： F840.684 C913.7

参考文献

[1] 国家医疗保障局.国家医保局2024年国家基本医疗保险、工伤保险和生育保险药品目录调整新闻发布会实录[EB/OL].(2024-11-28)[2026-01-16].https://www.nhsa.gov.cn/art/2024/11/28/art_14_14889.html.
[2] 英国商业贸易部.政府机构|DBT生命科学与医疗健康[EB/OL].[2026-01-16].https://healthcare.ukbusinessinchina.com/zhiyao/zhengfujigou.
[3] KHAN SK, GONZALEZ-MORAL SG, LANYI K et al. Closing the loop between horizon scanning and health technology assessment - an overview of topics submitted for appraisal in England[J]. International journal of technology assessment in health care, 2023, 39(1): e64.
[4] 宋源源,杜昕昱,李雨畅,等.英国“同情用药制度”分析及对我国的借鉴[J].中国药房,2024,35(09):1029-1033.
[5] The United Kingdom Office for Life Sciences. Early access to medicines scheme (EAMS): task group and principles [EB/OL]. (2016-05-10) [2026-01-16]. https://www.gov.uk/government/publications/early-access-to-medicines-scheme-eams-how-the-scheme-works/early-access-to-medicines-scheme-eams-task-group-and-principles.
[6] 姚嘉奇,周挺,管欣,等.英国NICE卫生技术评估介绍及对我国医保目录动态调整的启示[J].中国循证医学杂志,2018,18(09):984-989.
[7] National Institute for Health and Care Excellence. NICE technology appraisal and highly specialised technologies guidance: the manual [EB/OL]. (2025-12-17) [2026-01-16]. https://www.nice.org.uk/process/pmg36.
[8] NHS England. NHS commercial framework for new medicines [EB/OL]. (2025-01-31) [2026-01-16]. https://www.england.nhs.uk/long-read/nhs-commercial-framework-for-new-medicines/.
[9] 郑王彪,郑超,孙强.医保药品目录动态调整的国际经验与启示[J].卫生经济研究,2023,40(12):62-67.
[10] BALMAN E, MARSHALL JD. Managed Access Agreements (MAAS) in appraisals conducted by The National Institute For Health and Care Excellence (NICE)[J]. Value in health, 2017, 20(9): A704.
[11] National Institute for Health and Care Excellence. Processes and methods for NICE-wide guidance surveillance [EB/OL]. (2025-10-23) [2026-01-16]. https://www.nice.org.uk/process/pmg49/chapter/nice-wide-guidance-surveillance.
[12] National Institute for Health and Care Excellence. Guide to the processes of technology appraisal [EB/OL]. (2018-05-30) [2026-01-16]. https://www.nice.org.uk/process/pmg19/chapter/reviews.
[13] National Institute for Health and Care Excellence. Managed access [EB/OL]. (2025-08-19) [2026-01-16]. https://www.nice.org.uk/what-nice-does/patient-access-schemes-and-pricing-agreements/managed-access.
[14] NHS England. Building an integrated, rules-based medical technology (medtech) pathway: engagement on proposals [EB/OL]. (2024-05-23) [2026-01-16]. https://www.england.nhs.uk/long-read/building-an-integrated-rules-based-medical-technology-medtech-pathway-engagement-on-proposals/.
[15] NHS England. Fit for the future: 10 Year Health Plan for England - executive summary (accessible version) [EB/OL]. (2025-07-30) [2026-01-16]. https://www.gov.uk/government/publications/10-year-health-plan-for-england-fit-for-the-future/fit-for-the-future-10-year-health-plan-for-england-executive-summary.
[16] ODUNLAMI B, JAMESON K, RAFIA R, et al.HTA8 changes in NICE guidance following surveillance review: when, how and why?[J]. Value in health, 2024, 27(12): S354.
[17] CHUNARA F, WILSON C, FOXON G, et al.PDG43 are patient access schemes and commercial access agreements essential for NICE to recommend access? a comparison of oncology and non-oncology appraisals[J]. Value in Health, 2019, 22: S603.
[18] National Institute for Health and Care Excellence. NICE-wide topic prioritisation: the manual [EB/OL]. (2025-03-31) [2026-01-16]. https://www.nice.org.uk/process/pmg46.
[19] HASHIM S, AMADORI F, LEATHAM O.HTA273 managed access agreements in the UK: a detailed analysis of NICE's utilization and impact on access[J]. Value in health, 2023, 26(12): S373.
[20] KANG J, CAIRNS J."Don't think twice, it's all right": using additional data to reduce uncertainty regarding oncologic drugs provided through managed access agreements in England[J]. PharmacoEconomics open, 2023, 7(1): 77-91.
[21] MACAULAY R.Managed access agreements: a new model pathway for the reimbursement of non-oncology drugs in England approved under European adaptive pathways?[J]. Value in health, 2016, 19(7): A505.
[22] FARMER C, BARNISH MS, TRIGG LA, et al.An evaluation of managed access agreements in England based on stakeholder experience[J]. International journal of technology assessment in health care, 2023, 39(1): e55.
[23] 吕兰婷,张肇龙,王知,等.英国高值创新药支付保障机制研究与启示[J].中国医疗保险,2023(10):122-128.
[24] ALDERSON LJH, ALDERSON P, TAN T.Median life span of a cohort of National Institute for Health and Care Excellence clinical guidelines was about 60 months[J]. Journal of clinical epidemiology, 2014, 67(1): 52-55.
[25] CASEY M, RAYNOR M, JACOB C, et al.Improving the precision of search strategies for guideline surveillance[J]. Research synthesis methods, 2020, 11(6): 903-912.
[26] National Institute for Health and Care Excellence. National Institute for Health and Care Excellence Annual Report and Accounts2019/20 [R/OL]. (2020-06-07) [2026-01-16]. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/900350/nice-annual-report-and-accounts-2019-to-2020-print-version.pdf.
[27] National Institute for Health and Care Excellence. National Institute for Health and Care Excellence Annual Report and Accounts2020/21 [R/OL]. (2021-07-08) [2026-01-16]. https://assets.publishing.service.gov.uk/media/60e2c074e90e07717ccc075a/NICE_annual_report_and_accounts_2020_to_2021.pdf.
[28] TRIGG LA, BARNISH MS, HAYWARD S, et al.An analysis of uncertainties and data collection agreements in the Cancer Drugs Fund[J]. PharmacoEconomics open, 2024, 8(2): 303-311.
[29] 国家医疗保障局. 2025年度医保谈判收官:对真创新表达“真支持”[EB/OL].(2025-11-07)[2026-01-16].https://www.nhsa.gov.cn/art/2025/11/7/art_14_18559.html.
[30] 中国政府网.加速新药准入鼓励行业创新——解读新版国家医保药品目录[EB/OL].(2023-01-21)[2026-01-16]. https://www.gov.cn/zhengce/2023-01/21/content_5738317.htm.
[31] National Institute for Health and Care Excellence. NICE real-world evidence framework [EB/OL]. (2022-06-23) [2026-01-16]. https://www.nice.org.uk/corporate/ecd9.
[32] 国家药品监督管理局药品审评中心.国家药监局药审中心关于发布《用于产生真实世界证据的真实世界数据指导原则(试行)》的通告(2021年第27号)[EB/OL].(2021-04-13)[2026-01-16].https://www.cde.org.cn/main/news/viewInfoCommon/2a1c437ed54e7b838a7e86f4ac21c539.
[33] 国家医疗保障局.国家医疗保障局办公室关于开展真实世界医保综合价值评价试点工作的通知[EB/OL].(2025-09-23)[2026-01-16].https://www.nhsa.gov.cn/art/2025/9/23/art_109_17984.html.